Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of denosumab for breast cancer prevention in women with a BRCA1 mutation
MOH_2021-01-03_009632Phase 3Recruiting
- Sponsor
- דר' רחל מייקלסון-כהן
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Denosumab with Placebo (2 arms). Primary endpoint: Risk reduction of breast cancer. Started May 2020; status: recruiting.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2021-01-03_009632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-03_009632.